Overview

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Status:
Recruiting
Trial end date:
2022-04-25
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. The secondary objectives of the study are: - To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma - To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma
Phase:
Phase 4
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal